“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor activity in a majority of patients with relapsed or refractory multiple myeloma,” Yael C. Cohen ...
Combination therapy with teclistamab plus talquetamab showed encouraging antitumor activity in a majority of patients with relapsed or refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback